Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines

Prognosis of childhood acute lymphoblastic leukemia (ALL) has been dramatically improved. However, prognosis of the cases refractory to primary therapy is still poor. Recent phase 2 study on the efficacy of combination chemotherapy with bortezomib (BTZ), a proteasome inhibitor, for refractory childh...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :PLoS One
Главные авторы: Takahashi, Kazuya, Inukai, Takeshi, Imamura, Toshihiko, Yano, Mio, Tomoyasu, Chihiro, Lucas, David M., Nemoto, Atsushi, Sato, Hiroki, Huang, Meixian, Abe, Masako, Kagami, Keiko, Shinohara, Tamao, Watanabe, Atsushi, Somazu, Shinpei, Oshiro, Hiroko, Akahane, Koshi, Goi, Kumiko, Kikuchi, Jiro, Furukawa, Yusuke, Goto, Hiroaki, Minegishi, Masayoshi, Iwamoto, Shotaro, Sugita, Kanji
Формат: Artigo
Язык:Inglês
Опубликовано: Public Library of Science 2017
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728482/
https://ncbi.nlm.nih.gov/pubmed/29236701
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0188680
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы